Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | GCGR | P47871 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13799268 | 0.85 | CA1 (0.39) | CA1CA2TRPA1LMNACHRM1 | |
| SCHEMBL13812419 | 0.84 | CA1 (0.38) | CA1CA2TRPA1LMNACHRM1 | |
| SCHEMBL13799259 | 0.84 | AKR1C2 (0.39) | CA1CA2LMNARPS6KA3PTGS2 | |
| SCHEMBL13799256 | 0.81 | NPC1 (0.43) | RPS6KA3 | |
| SCHEMBL12447345 | 0.79 | TRPA1 (0.39) | CA1CA2TRPA1LMNACHRM1 | |
| SCHEMBL13614872 | 0.77 | ACHE (0.37) | LMNARPS6KA3PTGS2PTGS1ACHE | |
| SCHEMBL13377485 | 0.77 | TRPA1 (0.34) | CA1CA2TRPA1LMNACHRM1 | |
| SCHEMBL13799269 | 0.75 | GCGR (0.41) | CA1CA2GCGRACHE | |
| SCHEMBL15445309 | 0.73 | CA1 (0.71) | CA1CA2TRPA1LMNACHRM1 | |
| SCHEMBL15176931 | 0.73 | CA1 (0.71) | CA1CA2TRPA1LMNACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090145483-A1 | Novel electroluminescent compounds and organic electroluminescent device suing the same | GRACEL DISPLAY INC. (KR) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090145483-A1 | Novel electroluminescent compounds and organic electroluminescent device suing the same | LEF1, ODC1, AOC2 | CA1 2319/4885CA2 1446/4885TRPA1 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.